Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03506373 · ClinicalTrials.gov registry record · Phase 2
Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia
A Phase 2 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT03506373: Clinical Trial Phase 2 study, sponsored by Mayo Clinic.
NCT03506373 is a Phase 2 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03506373, a Phase 2 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
This phase II trial studies the side effects of ibrutinib citrate when given with ixazomib, and determines how well they work in treating patients with Waldenstrom macroglobulinemia that is newly diagnosed, has come back (recurrent) or does not respond to treatment (refractory). Enzyme inhibitors, such as ibrutinib and ixazomib citrate, may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Ibrutinib
- DRUG Ixazomib Citrate
- OTHER Pharmacokinetic Study
- OTHER Pharmacodynamic Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2018-08-14 |
| Est. Completion | 2026-02-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03506373
The ClinicalTrials.gov registry entry for NCT03506373 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT03506373 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03506373 about?
NCT03506373 is a clinical study titled "Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia". This phase II trial studies the side effects of ibrutinib citrate when given with ixazomib, and determines how well they work in treating patients with Waldenstrom macroglobulinemia that is newly diagnosed, has come back (recurrent) or does not respond to treatment (refractory). Enzyme inhibitors, s...
What is the current status of trial NCT03506373?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2018-08-14. Estimated completion is 2026-02-03.
What interventions are being tested in trial NCT03506373?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Ibrutinib (DRUG), Ixazomib Citrate (DRUG), Pharmacokinetic Study (OTHER), Pharmacodynamic Study (OTHER).
Who is sponsoring clinical trial NCT03506373?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.